Acta Naturae

SCImago Journal & Country Rank
SciteSore by SCOPUS

Acta Naturae is a new international journal on life sciences based in Moscow, Russia. Our goal is to present scientific work and discovery in molecular biology, biochemistry, biomedical disciplines and biotechnology. These fields represent the most important priorities for the research and engineering development both in Russia and worldwide. Acta Naturae is also a periodical for those who are curious in various aspects of biotechnological business, innovations in pharmaceutical areas, intellectual property protection and social consequences of scientific progress. The journal will publish analytical industrial surveys focused on the development of different spheres of modern life science and technology.

Being a radically new and totally unique publication in Russia, Acta Naturae will be useful to both representatives of fundamental research and experts in applied sciences.

The editorial council and editorial board include prominent scientists from Russia and abroad: Anatoly Grigoriev, Take Rolex vice-president of Russian Academy of sciences, Alexander Gabibov, Sergey Kochetkov, Patrick Masson, Alan Friboulet, Alfonso Tramontano, Knud Nierhaus.

The journal is published since April 2009, 4 times a year.

Announcements More Announcements...

 

Academician Anatoly I. Grigoriev passed away on February 11, 2023

Posted: 17.02.2023

The editorial board of the journal Acta Naturae informs with deep regret that on February 11, 2023, the founder of the journal, the permanent chairman of the editorial board, academician Anatoly I. Grigoriev, passed away.


 

Free Full Open Access to the jornal

Posted: 30.10.2019

Journal “Acta Naturae” is now available in open access in PubMed Central and eLIBRARY.RU.


 

Current Issue

Vol 16, No 4 (2024)

Cover Page

Reviews

Recombinant VSV as a promising tool for virotherapy
Vorona K.A., Moroz V.D., Gasanov N.B., Karabelsky A.
Abstract

This work presents information on the mechanisms of oncogenesis, the antiviral response in cancer and healthy cells, with special attention to markers of tumor cell resistance to VSV virotherapy. In addition, the review discusses methods of producing and arming recombinant VSV and provides examples of clinical trials. All the information gathered in this review will help researchers to assess the prospects for using VSVs as oncolytics and to develop safer and more effective anticancer drugs.

Acta Naturae. 2024;16(4):4-14
pages 4-14 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies